TuHURA Biosciences ( (HURA) ) just unveiled an announcement.
On March 10, 2025, TuHURA Biosciences appointed Dr. Craig Tendler to its Board of Directors, expanding the board to six members. Dr. Tendler brings extensive experience from his previous role at Johnson & Johnson, where he oversaw major drug approvals and FDA breakthrough designations in oncology. His expertise is expected to aid TuHURA in advancing its drug development programs and evaluating potential collaborations and acquisitions, particularly as the company prepares for a Phase 3 trial of its drug candidate IFx-2.0.
More about TuHURA Biosciences
TuHURA Biosciences, Inc. is a Phase 3 registration-stage immuno-oncology company focused on developing novel technologies to overcome primary and acquired resistance to cancer immunotherapy. The company is advancing its lead drug candidate, IFx-2.0, and preparing for a Phase 3 clinical trial to address resistance to checkpoint inhibitors.
YTD Price Performance: -48.42%
Average Trading Volume: 223,187
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $89.64M
See more insights into HURA stock on TipRanks’ Stock Analysis page.